Skip to main content
. 2022 Feb 22;12:3025. doi: 10.1038/s41598-022-07098-3

Figure 1.

Figure 1

Kaplan–Meier survival curves of overall survival (OS) and relapse-free survival (RFS) according to CRPmax in patients with stage II/III gastric cancer. (A) The five-year OS rates are 66.1% in the low-CRPmax group and 45.6% in the high-CRPmax group (p < 0.001). (B) The five-year RFS rates are 63.5% in the low-CRPmax group and 44.4% in the high-CRPmax group (p < 0.001).